The DOI matches its Crossref record; 336 of the 336 references it cites were found in a registry or an index.
Ligand-Targeted Drug Delivery
Abstract
Safety and efficacy constitute the major criteria governing regulatory approval of any new drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic agent with a targeting ligand that exhibits little affinity for healthy cells but high affinity for pathologic cells. The probability of regulatory approval can conceivably be further enhanced by exploiting the same targeting ligand, conjugated to an imaging agent, to select patients whose diseased tissues display sufficient targeted receptors for therapeutic efficacy. The focus of this Review is to summarize criteria that must be met during design of ligand-targeted drugs (LTDs) to achieve the required therapeutic potency with minimal toxicity. Because most LTDs are composed of a targeting ligand (e.g., organic molecule, aptamer, protein scaffold, or antibody), spacer, cleavable linker, and therapeutic warhead, criteria for successful design of each component will be described. Moreover, because obstacles to successful drug design can differ among human pathologies, limitations to drug delivery imposed by the unique characteristics of different diseases will be considered. With the explosion of genomic and transcriptomic data providing an ever-expanding selection of disease-specific targets, and with tools for high-throughput chemistry offering an escalating diversity of warheads, opportunities for innovating safe and effective LTDs has never been greater.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–336 of 336
Fisher, R. E., Siegel, B. A., Edell, S. L., Oyesiku, N. M., Morgenstern, D. E., Messmann, R. A., & Amato, R. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049478 · Cited by 143
Current methods for the synthesis of homogeneous antibody–drug conjugates
Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142
Folic Acid Conjugates for Nuclear Imaging of Folate Receptor–Positive Cancer
Müller, C., & Schibli, R. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076018 · Cited by 139
Kutcher, M., Xu, J., Vilardi, R. F., Ho, C., Esmon, C. T., & Cohen, M. J. M. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318270d595 · Cited by 137
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 135
Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research
Pouliot, M., & Jeanmart, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00361 · Cited by 132
Kashiwagi, H., McDunn, J. E., Simon, P. O., Goedegebuure, P. S., Xu, J., Jones, L. A., Chang, K. C., Johnston, F. M., Trinkaus, K. M., Hotchkiss, R. S., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-48 · Cited by 132
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
Heo, T., Wahler, J., & Suh, N. (2016) · Oncotarget · doi:10.18632/oncotarget.7102 · Cited by 127
Moody, P. R., Sayers, E. J., Magnusson, J. P., Alexander, C., Borri, P., Watson, P., & Jones, A. T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.178 · Cited by 124
Burke, P., Senter, P. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Toki, B. E., Manikumar, G., Wani, M. C., Kroll, D. J., & Jeffrey, S. C. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9001097 · Cited by 124
Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
Okeley, N. M., Toki, B. E., Zhang, X., Jeffrey, S. C., Burke, P., Alley, S. C., & Senter, P. D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4002695 · Cited by 120
Click Strategies for Single-Molecule Protein Fluorescence
Milles, S., Tyagi, S., Banterle, N., Koehler, C., VanDelinder, V., Plass, T., Neal, A. P., & Lemke, E. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210587q · Cited by 120
Yang, J. J. J., Chen, H., Vlahov, I. R., Cheng, J., & Low, P. S. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117648 · Cited by 117
Self-citationOjima, I. (2004) · ChemBioChem · doi:10.1002/cbic.200300844 · Cited by 116
Tsuneyoshi, Y., Tanaka, M., Nagai, T., Sunahara, N., Matsuda, T., Sonoda, T., Ijiri, K., Komiya, S., & Matsuyama, T. (2012) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2011.605391 · Cited by 116
Morris, R. T., Joyrich, R. N., Naumann, R. W., Shah, N. P., Maurer, A. H., Strausś, H. W., Uszler, J. M., Symanowski, J. T., Ellis, P. R., & Harb, W. A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu024 · Cited by 115
Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA
Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S., & Harashima, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.047 · Cited by 114
Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors.
Reddy, J. A., Xu, L.-C., Parker, N. L., Vetzel, M., & Leamon, C. P. (2004) · PubMed · Cited by 113
Ditsch, N. C., Tóth, B., Mayr, D. C., Lenhard, M., Gallwas, J. K. S., Weissenbacher, T. M., Dannecker, C., Friese, K., & Jeschke, U. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411429155 · Cited by 111
Effect of Folate-Targeted Nanoparticle Size on Their Rates of Penetration into Solid Tumors
Vlashi, E., Kelderhouse, L. E., Sturgis, J. E., & Low, P. S. (2013) · ACS Nano · doi:10.1021/nn402644g · Cited by 110
Self-citationHamblett, K. J., Kozlosky, C. J., Siu, S., Chang, W., Liu, H., Foltz, I. N., Trueblood, E. S., Meininger, D. P., Arora, T., Twomey, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1078 · Cited by 110
Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate
Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E. M., Dawson, A., Dorton, R., Vetzel, M., Santhapuram, H. K. R., & Wang, Y. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070049c · Cited by 109
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
Giles, F. J., Estey, E. H., & O'Brien, S. M. (2003) · Cancer · doi:10.1002/cncr.11791 · Cited by 108
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Ackerman, M. E., Pawlowski, D., & Wittrup, K. D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0067 · Cited by 107
Hock, M. B., Thudium, K. E., Carrasco‐Triguero, M., & Schwabe, N. F. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9684-6 · Cited by 106
Schmittgen, T. D., Teske, S., Vessella, R. L., True, L. D., & Zakrajsek, B. A. (2003) · International Journal of Cancer · doi:10.1002/ijc.11402 · Cited by 104
The evolving small‐molecule fluorescent‐conjugate toolbox for C lass A GPCRs
Vernall, A. J., Hill, S. J., & Kellam, B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12265 · Cited by 102
Use of Animal Models of Human Disease for Nonclinical Safety Assessment of Novel Pharmaceuticals
Morgan, S. J., Elangbam, C. S., Berens, S. J., Janovitz, E. B., Vitsky, A., Zabka, T. S., & Conour, L. A. (2012) · Toxicologic Pathology · doi:10.1177/0192623312457273 · Cited by 101
Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery
Malamas, A. S., Gujrati, M. D., Kummitha, C. M., Xu, R., & Lu, Z. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.06.019 · Cited by 100
Drug delivery and release systems for targeted tumor therapy
Böhme, D., & Beck‐Sickinger, A. G. (2015) · Journal of Peptide Science · doi:10.1002/psc.2753 · Cited by 99
A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
LoRusso, P. M., Edelman, M. J., Bever, S. L., Forman, K., Pilat, M., Quinn, M. F., Li, J., Heath, E. I., Malburg, L., Klein, P. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4946 · Cited by 98
Kolmar, H. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06440.x · Cited by 97
Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A. U., & Rader, C. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021018 · Cited by 97
Protease‐resistant peptide design—empowering nature's fragile warriors against HIV
Weinstock, M. T., Francis, J. N., Redman, J. S., & Kay, M. S. (2012) · Biopolymers · doi:10.1002/bip.22073 · Cited by 97
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Winkler, J., Martin-Killias, P., Plückthun, A., & Zangemeister‐Wittke, U. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0402 · Cited by 97
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
Goldstein, R., Sosabowski, J. K., Livanos, M., Leyton, J., Vigor, K., Bhavsar, G., Nagy‐Davidescu, G., Rashid, M., Miranda, E., Yeung, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2940-2 · Cited by 95
Nj, B., Farries, T., Gharagozloo, P., Kobayashi, S., Lazareno, S., & Sugimoto, M. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23041-8 · Cited by 94
Marcucci, F., & Corti, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.007 · Cited by 94
Managit, C., Kawakami, S., Yamashita, F., & Hashida, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20443 · Cited by 93
Design of novel FN3 domains with high stability by a consensus sequence approach
Jacobs, S. A., Diem, M. D., Luo, J., Teplyakov, A., Obmolova, G., Malia, T., Gilliland, G. L., & O’Neil, K. T. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzr064 · Cited by 92
Moore, R. H., Sadovnikoff, N., Hoffenberg, S., Liu, S., Woodford, P., Angelides, K. J., Trial, J., Carsrud, N. D. V., Dickey, B. F., & Knoll, B. J. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.9.2983 · Cited by 92
Engineering of Affibody Molecules for Therapy and Diagnostics
Feldwisch, J., & Tolmachev, V. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_7 · Cited by 91
Koefoed, K., Steinaa, L., Søderberg, J. N., Kjær, I., Jacobsen, H. J., Meijer, P., Haurum, J. S., Jensen, A. D., Kragh, M., Andersen, P. S., et al. (2011) · mAbs · doi:10.4161/mabs.3.6.17955 · Cited by 91
Gnagey, A. L., Seidenberg, M., & Ellis, J. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1245 · Cited by 91
Chemical, Target, and Bioactive Properties of Allosteric Modulation
van Westen, G. J. P., Gaulton, A., & Overington, J. P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003559 · Cited by 90
Baker, M. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1065 · Cited by 90
Mutagenesis and selection of PDZ domains that bind new protein targets
Schneider, S., Büchert, M., Georgiev, O., Catimel, B., Halford, M. M., Stacker, S. A., Baechi, T., Moelling, K., & Hovens, C. M. (1999) · Nature Biotechnology · doi:10.1038/6172 · Cited by 87
Self‐Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol‐Free Drugs
Frich, C. K., Autzen, A. A. A., & Zelikin, A. N. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500344 · Cited by 87
Gregorc, V., Santoro, A., Bennicelli, E., Punt, C. J. A., Citterio, G., Timmer-Bonte, J. N. H., Cappio, F. C., Lambiase, A., Bordignon, C., & van Herpen, C. M. L. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605162 · Cited by 86
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
Ding, X., 杨连粤, Huang, G.-W., Wang, W., & Lu, W.-Q. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i18.2735 · Cited by 83
The use of shear stress for targeted drug delivery
Saxer, T., Zumbuehl, A., & Müller, B. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt102 · Cited by 83
Multivalent Ligand: Design Principle for Targeted Therapeutic Delivery Approach
Chittasupho, C. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.99 · Cited by 82
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
Smith, A. M., Manoli, H., Jaw, S., Frutoz, K., Epstein, A. L., Khawli, L. A., & Theil, F. (2016) · Journal of Immunology Research · doi:10.1155/2016/2342187 · Cited by 81
Li, J., Sausville, E. A., Klein, P., Morgenstern, D. E., Leamon, C. P., Messmann, R. A., & LoRusso, P. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339740 · Cited by 80
Comparative preclinical activity of the folate‐targeted Vinca alkaloid conjugates EC140 and EC145
Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E. M., Parker, N. L., Nicoson, J. S., & Vetzel, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22853 · Cited by 79
Multiplex target protein imaging in tissue sections by mass spectrometry – TAMSIM
Thiery, G., Shchepinov, M. S., Southern, E. M., Audebourg, A., Audard, V., Terris, B., & Gut, I. G. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2895 · Cited by 79
Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
Roosenburg, S., Laverman, P., van Delft, F. L., & Boerman, O. C. (2010) · Amino Acids · doi:10.1007/s00726-010-0501-y · Cited by 78
Hornick, J. R., Xu, J., Vangveravong, S., Tu, Z., Mitchem, J. B., Spitzer, D., Goedegebuure, P. S., Mach, R. H., & Hawkins, W. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-298 · Cited by 78
Bryden, F., Maruani, A., Savoie, H., Chudasama, V., Smith, M. E. B., Caddick, S., & Boyle, R. W. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5000324 · Cited by 76
Animal Models for Human Diseases
Hau, J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_1 · Cited by 74
Emanuel, S. L., Engle, L. J., Chao, G., Zhu, R.-R., Cao, C., Lin, Z., Yamniuk, A. P., Hosbach, J., Brown, J. M., Fitzpatrick, E., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.14168 · Cited by 74
The emerging role of new protein scaffold-based agents for treatment of cancer.
Weidle, U. H., Auer, J., Brinkmann, U., Georges, G. J., & Tiefenthaler, G. (2013) · PubMed · Cited by 74
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents
Jeffrey, S. C., Brabander, J. K. D., Miyamoto, J. B., & Senter, P. D. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100039h · Cited by 73
Lu, Y. J., Sega, E. I., & Low, P. S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21126 · Cited by 73
Self-citationLeamon, C. P., Reddy, J. A., Dorton, R., Bloomfield, A., Emsweller, K., Parker, N. L., & Westrick, E. M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143206 · Cited by 73
Folate–Vinca Alkaloid Conjugates for Cancer Therapy: A Structure–Activity Relationship
Leamon, C. P., Vlahov, I. R., Reddy, J. A., Vetzel, M., Santhapuram, H. K. R., You, F., Bloomfield, A., Dorton, R., Nelson, M., Kleindl, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400441s · Cited by 70
Quiles, S., Raisch, K. P., Sanford, L. L., Bonner, J. A., & Safavy, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900899g · Cited by 70
Maurer, A. H., Elsinga, P. H., Fanti, S., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.133074 · Cited by 70
Release of Soluble Urokinase Receptor from Vascular Cells*
Chavakis, T., Willuweit, A., Lupu, F., Preissner, K. T., & Kanse, S. M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616105 · Cited by 70
Johansson, P. I., Windeløv, N. A., Rasmussen, L. S., Sørensen, A., & Ostrowski, S. R. (2013) · Journal of Emergencies Trauma and Shock · doi:10.4103/0974-2700.115327 · Cited by 69
Dineen, S. P., Sullivan, L. A., Beck, A. W., Miller, A. F., Carbon, J. G., Mamluk, R., Wong, H., & Brekken, R. A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-352 · Cited by 68
Shinmi, D., Taguchi, E., Iwano, J., Yamaguchi, T., Masuda, K., Enokizono, J., & Shiraishi, Y. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00133 · Cited by 67
Lehmann, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1187 · Cited by 66
Lagarrigue, F., Dupuis-Coronas, S., Ramel, D., Delsol, G., Tronchère, H., Payrastre, B., & Gaits‐Iacovoni, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0861 · Cited by 66
Diem, M. D., Hyun, L., Yi, F., Hippensteel, R., Kuhar, E., Lowenstein, C. L., Swift, E. J., O’Neil, K. T., & Jacobs, S. A. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu016 · Cited by 65
Cheng, B., Montmasson, M., Terradot, L., & Rousselle, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00010 · Cited by 65
Nilvebrant, J., Åstrand, M., Georgieva-Kotseva, M., Björnmalm, M., Löfblom, J., & Hober, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103094 · Cited by 62
Therapeutic aptamers: developmental potential as anticancer drugs
Lee, J. W., Kim, H. J., & Heo, K. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.4.277 · Cited by 61
Briasoulis, E. C., Judson, I. R., Pavlidis, N. A., Beale, P. J., Wanders, J., Groot, Y., Veerman, G., Schuessler, M., Niebch, G., Siamopoulos, K. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3535 · Cited by 61
Affilin–Novel Binding Molecules Based on Human γ-B-Crystallin, an All β-Sheet Protein
Ebersbach, H., Fiedler, E., Scheuermann, T., Fiedler, M. R. M., Stubbs, M. T., Reimann, C., Proetzel, G., Rudolph, R., & Fiedler, U. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.045 · Cited by 59
Kesely, K. R., Pantaleo, A., Turrini, F. M., Olupot‐Olupot, P., & Low, P. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164895 · Cited by 59
Self-citationPrognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis
Templeton, A. J., Díez-González, L., Ace, O., Vera-Badillo, F., Šeruga, B., Jordán, J., Amir, E., Pandiella, A., & Ocaña, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.08.003 · Cited by 58
Folate receptor-β constitutes a marker for human proinflammatory monocytes
Shen, J., Hilgenbrink, A. R., Xia, W. G., Feng, Y., Dimitrov, D. S., Lockwood, M. B., Amato, R. J., & Low, P. S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ab0713-372r · Cited by 58
Self-citationThird-Generation Antibody Drug Conjugates for Cancer Therapy–A Balancing Act
Vankemmelbeke, M. N., & Durrant, L. G. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0002 · Cited by 58
Pan-Cancer Analyses of the Nuclear Receptor Superfamily
Long, M. D., & Campbell, M. J. (2015) · Nuclear Receptor Research · doi:10.11131/2015/101182 · Cited by 57
Zhang, D., Pillow, T. H., Ma, Y., Cruz-Chuh, J. D., Kozak, K. R., Sadowsky, J., Phillips, G. D. L., Guo, J., Darwish, M., Fan, P. W., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00233 · Cited by 57
Shao, L., Liu, S., Hou, J., Yan-hua, Z., Peng, C., Zhong, Y.-J., Liu, X., Liu, X., Hong, Y., Firestone, R. A., et al. (2011) · Cancer · doi:10.1002/cncr.26596 · Cited by 54
Fani, M., Tamma, M., Nicolas, G. P., Lasri, E., Medina, C., Raynal, I., Port, M., Weber, W., & Maëcke, H. R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200418f · Cited by 54
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Herrington-Symes, A. P., Farys, M., Khalili, H., & Brocchini, S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.45090 · Cited by 53
Use of Allosteric Targets in the Discovery of Safer Drugs
Grover, A. K. (2013) · Medical Principles and Practice · doi:10.1159/000350417 · Cited by 53
Effect of Receptor Occupancy on Folate Receptor Internalization
Bandara, N. A., Hansen, M. J., & Low, P. S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400659t · Cited by 52
Self-citationFarkas, R., Siwowska, K., Ametamey, S. M., Schibli, R., van der Meulen, N. P., & Müller, C. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00143 · Cited by 51
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics
Kumar, A., Mastren, T., Wang, B., Hsieh, J., Hao, G., & Sun, X. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00222 · Cited by 51
SITE-SPECIFIC FUNCTIONALIZATION OF PROTEINS AND THEIR APPLICATIONS TO THERAPEUTIC ANTIBODIES
van Vught, R., Pieters, R. J., & Breukink, E. J. (2014) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201402001 · Cited by 49
Production of Novel Recombinant Single-Domain Antibodies against Tandem Repeat Region of MUC1 Mucin
Rahbarizadeh, F., Rasaee, M. J., Moghadam, M. F., Allameh, A., & Sadroddiny, E. (2004) · Hybridoma and Hybridomics · doi:10.1089/1536859041224334 · Cited by 49
Wayua, C., & Low, P. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400429h · Cited by 49
Self-citationMauris, J., Mantelli, F., Woodward, A. M., Ziyhi, C., Bertozzi, C. R., Panjwani, N., Godula, K., & Argüeso, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072304 · Cited by 48
Leamon, C. P., Reddy, J. A., Klein, P., Vlahov, I. R., Dorton, R., Bloomfield, A., Nelson, M., Westrick, E. M., Parker, N. L., Bruna, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175109 · Cited by 47
Effect of an immunotoxin to folate receptor β on bleomycin-induced experimental pulmonary fibrosis
Nagai, T., Tanaka, M., Hasui, K., Shirahama, H., Kitajima, S., Yonezawa, S., Xu, B., & Matsuyama, T. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04182.x · Cited by 45
van den Bent, M. J., Grisold, W., Frappaz, D., Stupp, R., Desir, J. P., Lesimple, T., Dittrich, C., de Jonge, M. J. A., Brandes, A. A., Frénay, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg491 · Cited by 42
Quantitative Measurement of the Target-Mediated Internalization Kinetics of Biopharmaceuticals
Vainshtein, I., Roskos, L. K., Cheng, J. C., Sleeman, M. A., Wang, B., & Liang, M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1462-8 · Cited by 41
Anticalins as an alternative to antibody technology
Schlehuber, S., & Skerra, A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.11.1453 · Cited by 41
Mateo, C., Lombardero, J., Moreno, E., Morales, A., Bombino, G., Coloma, J., Wims, L. A., Morrison, S. L., & Pérez, R. (2000) · Hybridoma · doi:10.1089/027245700750053959 · Cited by 41
PEGylation of Antibody Fragments for Half-Life Extension
Jevševar, S., Kusterle, M., & Kenig, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-931-0_15 · Cited by 40
Folate-Targeted Hapten Immunotherapy of Adjuvant-Induced Arthritis: Comparison of Hapten Potencies
Yi, Y., Ayala-López, W., Kularatne, S. A., & Low, P. S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900070b · Cited by 39
Self-citationSpotting and designing promiscuous ligands for drug discovery
Schneider, P., Röthlisberger, M., Reker, D., & Schneider, G. (2015) · Chemical Communications · doi:10.1039/c5cc07506h · Cited by 37
Single‐Triggered Trimeric Prodrugs
Haba, K., Popkov, M., Shamis, M., Lerner, R. A., Barbas, C. F., & Shabat, D. (2005) · Angewandte Chemie · doi:10.1002/ange.200461657 · Cited by 37
Synthesis and NMR solution structure of an α‐helical hairpin stapled with two disulfide bridges
Barthe, P., Roumestand, C., Rochette, S., & Vita, C. (2000) · Protein Science · doi:10.1110/ps.9.5.942 · Cited by 35
Guillemard, V., Nedev, H. N., Berezov, A., Murali, R., & Saragovi, H. U. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.351 · Cited by 34
McCallum, M. M., Nandhikonda, P., Temmer, J. J., Eyermann, C. J., Simeonov, A. M., Jadhav, A., Yasgar, A., Maloney, D. J., & Arnold, A. (. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113476090 · Cited by 34
Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma.
Sano, K., Takayama, T., Murakami, K., Saiki, I., & Makuuchi, M. (2003) · PubMed · Cited by 31
Wayua, C., Roy, J., Putt, K. S., & Low, P. S. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00218 · Cited by 31
Self-citationAntibody Targeting of Cell-Bound MUC1 SEA Domain Kills Tumor Cells
Pichinuk, E., Benhar, I., Jacobi, O., Chalik, M., Weiss, L., Ziv, R., Sympson, C. J., Karwa, A. S., Smorodinsky, N. I., Rubinstein, D. B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0067 · Cited by 30
Stivarou, T., Stellas, D., Vartzi, G., Thomaidou, D., & Patsavoudi, E. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1195041 · Cited by 29
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
Leamon, C., Lovejoy, & Nguyen, N. T. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s24943 · Cited by 27
Qiu, C., Shan, L., Yu, M., & Snyderwine, E. G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi013 · Cited by 27
Kanduluru, A. K., Srinivasarao, M., & Low, P. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00374 · Cited by 26
Self-citationFigure Ground Discrimination in Age-Related Macular Degeneration
Tran, T. H. C., Guyader, N., Guérin-Dugué, A., Despretz, P., & Boucart, M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6003 · Cited by 25
Furusho, Y., Miyata, M., Matsuyama, T., Nagai, T., Li, H., Akasaki, Y., Hamada, N., Miyauchi, T., Ikeda, Y., Shirasawa, T., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003079 · Cited by 25
Dimerization drives EGF receptor endocytosis through two sets of compatible endocytic codes
Wang, Q., Chen, X., & Wang, Z. (2015) · Journal of Cell Science · doi:10.1242/jcs.160374 · Cited by 24
Ekholm, F. S., Pynnönen, H., Vilkman, A., Pitkänen, V., Helin, J., Saarinen, J., & Satomaa, T. (2016) · ChemMedChem · doi:10.1002/cmdc.201600372 · Cited by 24
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
Heertum, R. V., Scarimbolo, R., Ford, R., Berdougo, E., & O'Neal, J. M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87561 · Cited by 21
Tumor-Targeting Antibody–Anticalin Fusion Proteins for in Vivo Pretargeting Applications
Steiner, M., Gutbrodt, K. L., Krall, N., & Neri, D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300567a · Cited by 19
Jeong, K. J., Mabry, R., & Georgiou, G. (2005) · Nature Biotechnology · doi:10.1038/nbt1205-1493 · Cited by 18
Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity
Schubert, I. A., Stein, C., & Fey, G. H. (2012) · Antibodies · doi:10.3390/antib1010002 · Cited by 17
Hong, L. P. T., Scoble, J. A., Doughty, L., Coia, G., & Williams, C. C. (2011) · Australian Journal of Chemistry · doi:10.1071/ch11071 · Cited by 16
Kelderhouse, L. E., Robins, M. T., Rosenbalm, K. E., Hoylman, E. K., Mahalingam, S. M., & Low, P. S. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00134 · Cited by 16
Self-citationThe Clinical Landscape of Antibody-drug Conjugates
Rostami, S., Qazi, I., & Sikorski, R. S. (2014) · ADC Review / Journal of Antibody-drug Conjugates · doi:10.14229/jadc.2014.8.1.001 · Cited by 15
Hanna, N. H., Juhász, É., Cainap, C. I., Gladkov, O. A., Ramlau, R., Juan, Ó., Lal, R., Symanowski, J. T., Perez, W., Nguyen, B., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.48 · Cited by 12
Bandara, N. A., Bates, C. D., Lu, Y. J., Hoylman, E. K., & Low, P. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0569 · Cited by 10
Self-citationLin, N., Zheng, W., Li, L., Liu, H., Wang, T., Wang, P., & Ma, X. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0282-9 · Cited by 9
Non‐Antibody Scaffolds as Alternative Therapeutic Agents
Fiedler, M. R. M., & Skerra, A. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch17 · Cited by 8
Antibody–Drug Conjugates ( ADCs ) in Clinical Development
McLaughlin, J. F., & LoRusso, P. M. (2016) · doi:10.1002/9781119060727.ch13 · Cited by 3
Allosteric Interactions at GABAB and Related G-Protein–Coupled Receptors
Kerr, D. I. B., & Ong, J. A. (2006) · Informa Healthcare eBooks · doi:10.1201/9781420016185.ch11 · Cited by 2
Cited by
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives
Li, L., Xu, S., Yan, H., Li, X., Yazd, H. S., Li, X., Huang, T., Cui, C., Jiang, J., & Tan, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202003563 · Cited by 432
Versatile Types of Organic/Inorganic Nanohybrids: From Strategic Design to Biomedical Applications
Zhao, N., Yan, L., Zhao, X., Chen, X., Li, A., Zheng, D., Zhou, X., Dai, X., & Xu, F.-J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00401 · Cited by 429
Metadata
- Authors
- Srinivasarao, M., & Low, P. S.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-09-12
- Volume
- 117
- Issue
- 19
- Pages
- 12133-12164
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2754938970
- Cited by
- 605
- References
- 336
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.